Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection. We aimed to elucidate the treatment rate, factors affecting treatment decisions, and efficacy of interferon- based therapy in a real-world setting. Methods: This nationwide cohort study included 1,191 newly diagnosed patients with chronic HCV infection at seven tertiary hospitals in South Korea. Subjects were followed retrospectively until March 2015, which was just before the approval of DAA therapy. Results: In total, 48.2% and 49.3% of the patients had HCV genotypes 1 and 2, respectively. Interferon-based therapy was initiated in 541 patients (45.4%). The major reasons for no treatment included ineligibility (18.9%), concern about adverse events (22.3%), cost (21.5%), and an age >75 years (19.5%). Interferon-based therapy was discontinued (18.5%) mainly due to adverse events (n=66). The intent-to-treat analysis found that the sustained virologic response (SVR) rate was 58.3% in genotype 1 patients and 74.7% in nongenotype 1 patients. Conclusions: Approximately one-third of newly diagnosed HCV patients in South Korea received interferon-based therapy and showed a suboptimal SVR rate. Diagnosis of patients at younger ages and with a less advanced liver status and reducing the DAA therapy cost may fulfill unmet needs.
Abstract
Background/Aims: To evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection. We aimed to elucidate the treatment rate, factors affecting treatment decisions, and efficacy of interferon- based therapy in a real-world setting. Methods: This nationwide cohort study included 1,191 newly diagnosed patients with chronic HCV infection at seven tertiary hospitals in South Korea. Subjects were followed retrospectively until March 2015, which was just before the approval of DAA therapy. Results: In total, 48.2% and 49.3% of the patients had HCV genotypes 1 and 2, respectively. Interferon-based therapy was initiated in 541 patients (45.4%). The major reasons for no treatment included ineligibility (18.9%), concern about adverse events (22.3%), cost (21.5%), and an age >75 years (19.5%). Interferon-based therapy was discontinued (18.5%) mainly due to adverse events (n=66). The intent-to-treat analysis found that the sustained virologic response (SVR) rate was 58.3% in genotype 1 patients and 74.7% in nongenotype 1 patients. Conclusions: Approximately one-third of newly diagnosed HCV patients in South Korea received interferon-based therapy and showed a suboptimal SVR rate. Diagnosis of patients at younger ages and with a less advanced liver status and reducing the DAA therapy cost may fulfill unmet needs.
참고문헌 (22)
- Mohd Hanafiah K, "Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence", Hepatology, 57, pp.1333~1342 (2013)
- Stanaway JD, "The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013", Lancet, 388, pp.1081~1088 (2016)
- Wedemeyer H, "Strategies to manage hepatitis C virus (HCV) disease burden", J Viral Hepat, 21(Suppl 1), pp.60~89 (2014)
- Lyoo K, "Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin", J Clin Virol, 52, pp.363~366 (2011)
- 정석후, "Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C", Clinical and Molecular Hepatology, 18(4), pp.360~367 (2012), 대한간학회[DOI]
- Jung YK, "Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans", J Clin Gastroenterol, 47, pp.644~650 (2013)
- Hawks L, "The hepatitis C virus treatment cascade at an urban postincarceration transitions clinic", J Viral Hepat, 23, pp.473~478 (2016)
- Yu ML, "Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan", Medicine (Baltimore), 94, pp.e690~ (2015)
- Suk KT, "Revision and update on clinical practice guideline for liver cirrhosis", Korean J Hepatol, 18, pp.1~21 (2012)
- Lee JM, "2014 KLCSG-NCC Korea Practice Guidelines for the management of hepatocellular carcinoma: HCC diagnostic algorithm", Dig Dis, 32, pp.764~777 (2014)
- Jepsen P, "Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study", Hepatology, 48, pp.214~220 (2008)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Gundlapalli AV, "Correlates of initiation of treatment for chronic hepatitis C infection in United States veterans, 2004-2009", PLoS One, 10, pp.e0132056~ (2009)
- Jung YK, "Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C", Clin Mol Hepatol, 19, pp.26~28 (2013)
- Talal AH, "Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45000 HCV-infected, evaluated patients", Aliment Pharmacol Ther, 37, pp.473~481 (2013)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Hadziyannis SJ, "Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Borroni G, "Effectiveness of pegylated interferon", ribavirin combination in ‘real world’ patients with chronic hepatitis C virus infection, 2008, pp.27, 790~797
- "Reimbersement guide for current available drugs" (2016)[URL]
- Lee SS, "Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea", J Med Virol, 88, pp.275~281 (2016)
- Rangnekar AS, "IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis", J Viral Hepat, 20, pp.377~384 (2013)
- 박수용, "만성 C형간염 환자에서 페그인터페론과 리바비린 병합요법의 치료 효과: 통합 분석", 대한소화기학회지, 60(5), pp.306~314 (2012), 대한소화기학회